27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Cognitive decline is closely associated with biological aging and with interconnected processes, including chronic low-grade inflammation, oxidative stress, mitochondrial dysfunction, and cellular senescence. 2 key findings →
Design: narrative review Evidence: high
Full summary, score breakdown and related studies → Original source
This global study estimated how much dementia costs the world, combining formal healthcare spending with the value of unpaid family caregiving across 204 countries. 4 key findings →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source
Using three decades of global health data, this study tracked how young-onset dementia (before age 65) has changed since 1990. 5 key findings →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source
BackgroundThere are 5.5 million people living with dementia in the United States (US), with the cost of unpaid care making up a significant portion of the care costs. 2 key findings →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Current annual replacement cost of unpaid family care is between $96 and $182 billion, 44% of which is accounted for by dementia caregiving. 1 key finding →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
As the population ages, the number of people with dementia is expected to increase in the coming decades, with consequences at the societal and individual levels. 4 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
These findings suggest that HB-CCT via Neurotablet can effectively enhance specific cognitive abilities in PD, supporting the role of digital, home-based interventions as feasible strategies to mitigate cognitive decline. 4 key findings →
Design: post-hoc analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The mean age of the participants was 68 ± 9 years and 39% were female. 5 key findings →
Design: post-hoc analysis Participants: 759 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The amount of time spent in poor health at the end of life is increasing. 2 key findings →
Design: narrative review Evidence: high
Full summary, score breakdown and related studies → Original source
The Inflation Reduction Act Medicare Part D benefit redesign will reduce OOP drug spending for beneficiaries with dementia, resulting in potentially marked savings not only for low-income beneficiaries and beneficiaries with a high comorbidity burden but also for higher-income beneficiaries. 1 key finding →
Design: modelling Participants: 1,677 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
It is a piece of evidence that cognitive dysfunction, even in early stage of memory decline, may have some bad impact on balance and gait regardless of the effect of musculoskeletal problems. 5 key findings →
Design: post-hoc analysis Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Vascular dementia (VaD) is the second leading cause of dementia after Alzheimer's disease (AD). 1 key finding →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
To investigate amyloid-β (Aβ) in frontotemporal dementia (FTD), cerebrospinal fluid (CSF) Aβ38, Aβ40, and Aβ42 in frontotemporal lobar degeneration (FTLD; N = 18 genetically and/or pathologically confirmed and N = 8 FTD with concomitant amyotrophic lateral sclerosis) were compared with Alzheimer's disease (AD; pathological or Pittsburgh-compound-B Positron-emission-tomography (PIB-PET) positive; N = 25) and controls (N = 24). 3 key findings →
Design: post-hoc analysis Participants: 18 Evidence: low
Full summary, score breakdown and related studies → Original source
A total of 13 case reports were found (10 for donepezil, 2 for galantamine and 1 for rivastigmine) with rate corrected QT interval (QTc) prolongation. 5 key findings →
Design: case report Participants: 13 Evidence: low
Full summary, score breakdown and related studies → Original source
Multidomain interventions were associated with improvements on locomotion (as measured by performance-based tests of lower-limb function) and vitality (as measured by handgrip strength); benefits on cognitive function were also found, in particular among populations at increased risk of dementia and when operationalizing strong multidomain interventions (eg, using regular exercise training instead of physical activity advices). 5 key findings →
Design: narrative review Evidence: high
Full summary, score breakdown and related studies → Original source
Obesity is a significant health crisis affecting more than 123 million adults and children/adolescents in the US. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
Donanemab provides clinical benefits but is unlikely to be cost-effective under current Australian thresholds. 3 key findings →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The results project substantial cost savings from implementing a blood test for AD pathology within the diagnostic pathway based on modeling results, which future research should confirm with actual data. 4 key findings →
Design: modelling Evidence: preliminary
Full summary, score breakdown and related studies → Original source Free full text
Monoclonal antibodies such as lecanemab and donanemab show reduction in amyloid plaque and slowing of cognitive and functional decline (modest) in early AD (mild cognitive impairment or mild dementia). 5 key findings →
Design: narrative review Evidence: high
Full summary, score breakdown and related studies → Original source
Neuroaxonal damage underlies permanent disability in various neurological conditions, both neuroautoimmune and neurodegenerative. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Amyloid plaques and tau tangles are the hallmark pathologic features of Alzheimer's disease (AD). 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
The development of humanized IgG1 anti-amyloid monoclonal antibodies, such as lecanemab, provides a promising novel treatment pathway with potential disease-modifying effects for patients with early Alzheimer's disease (AD). 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
This case report is of a two-time stroke survivor with significant health comorbidities. 2 key findings →
Design: case report Evidence: low
Full summary, score breakdown and related studies → Original source
Burden of chronic intravenous treatments exceed the gross medical and social care cost savings and value of caregiver benefit. 3 key findings →
Design: modelling Evidence: preliminary
Full summary, score breakdown and related studies → Original source Free full text
Corticosteroids are widely used in modern medicine but can result in troubling psychiatric side-effects. 3 key findings →
Design: case report Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →